<DOC>
	<DOCNO>NCT00189683</DOCNO>
	<brief_summary>To compare maintenance chemotherapy Xeloda control best response first line chemotherapy advance colorectal cancer . Main endpoint progression free survival . A total 300 patient include .</brief_summary>
	<brief_title>Xeloda Vs Monitoring Advanced Colorectal Cancer Responsive Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>Patients metastatic colorectal cancer ( confirm histologically ) objective response stabilization least 6 cycle first line chemotherapy ( treatment choice select freely investigator accord recommendation consensus force ) , The interval completion first line chemotherapy randomization exceed 4 week Age &gt; 18 year ECOG status 0 2 Biological criterion prior chemotherapy : Neutrophils &gt; 1.5 109 g/l , platelet &gt; 100 109/l , haemoglobin &gt; 10 g/dl , Creatininaemia &lt; 150 ÔÅ≠mol/l , bilirubinaemia &lt; 2x normal level Signed inform consent Life expectancy &gt; 3 month Metastatic colorectal cancer treat one modality first line chemotherapy ( include oral fluoropyrimidines ) Tumour progression first line chemotherapy randomization Other tumour pathology Symptomatic cerebral metastasis Any severe uncontrolled disease addition colorectal cancer ( particular decompensated cardiac failure ( LVEF &lt; 50 % ) coronary insufficiency ) Lack integrity upper GI tract : malabsorption syndrome major surgery stomach small intestine Severe renal impairment ( creatinine clearance &lt; 30 ml/min ) Severe psychiatric disorder ( control depressive syndrome ) Patient participate another experiment Pregnant woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2005</verification_date>
</DOC>